Results 201 to 210 of about 2,596,436 (306)

Optimizing care and quality indicators in the management of patients with acute ischaemic heart disease and atherothrombotic stroke: measuring to improve. [PDF]

Drugs Context
González-Juanatey JR, Vázquez-García R, Campuzano R, Zamorano JL, Egocheaga MI, Pascual Fuster V, Martín Sanz A, Pedragosa Vall A, Masjuan J.   +8 more
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Development of AWaRe antibiotic quality indicators for optimal use

Heath A, Goelen J, Chuki P, Cook A, Djukic F, Thuy Do NT, Funiciello E, Gaundra S, Godman B, Huttner B, Khalaf YM, Lorenzetti G, Mendelson M, Moore CE, Osorio-de-Castro CG, Saleem Z, Schouten J, Tayler E, Wesangula E, AWaRe-Based QIs Delphi Panel, Campbell SM, Sharland M.   +21 more
europepmc   +1 more source

Artificial intelligence in colonoscopy: Enhancing quality indicators for optimal patient outcomes. [PDF]

World J Gastroenterol
Dimopoulou K, Spinou M, Ioannou A, Nakou E, Zormpas P, Tribonias G.   +5 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Evaluation of the population based integrated Care System “Gesundes Kinzigtal”: Results from the health care utilisation study over six years of observation

International Journal of Integrated Care, 2015
Ingrid Schubert, Peter Ihle, Ingrid Koester   +2 more
doaj   +1 more source

Quality indicators for rural surgical and obstetrical care: A modified Delphi consensus study. [PDF]

PLoS One
Parajulee A, Souraya A, Humber N, Ebert S, Williams K, Skinner T, Kornelsen J.   +6 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

National recommendations of the Working Group for Postanalytics of the Croatian Society of Medical Biochemistry and Laboratory Medicine: Quality indicators of the postanalytical phase. [PDF]

Biochem Med (Zagreb)
Podolar S, Vlašić Tanasković J, Jokić A, Honović L, Rimac V, Leniček Krleža J.   +5 more
europepmc   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source